Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Richard J. O'Brien"'
Autor:
Aida Kamalian, Sara G. Ho, Megha Patel, Alexandria Lewis, Arnold Bakker, Marilyn Albert, Richard J. O’Brien, Abhay Moghekar, Michael W. Lutz
Publikováno v:
Biomolecules, Vol 13, Iss 7, p 1094 (2023)
(1) Background: Despite the existence of well-established, CSF-based biomarkers such as amyloid-β and phosphorylated-tau, the pathways involved in the pathophysiology of Alzheimer’s disease (AD) remain an active area of research. (2) Methods: We m
Externí odkaz:
https://doaj.org/article/ecf717b7883040bfae72c947d41fce94
Autor:
Robert J. Anderson, Christopher M. Long, Evan D. Calabrese, Scott H. Robertson, G. Allan Johnson, Gary P. Cofer, Richard J. O'Brien, Alexandra Badea
Publikováno v:
Frontiers in Physics, Vol 8 (2020)
Network approaches provide sensitive biomarkers for neurological conditions, such as Alzheimer's disease (AD). Mouse models can help advance our understanding of underlying pathologies, by dissecting vulnerable circuits. While the mouse brain contain
Externí odkaz:
https://doaj.org/article/b6c62c3adcd04a21b8636dd8367f9675
Autor:
Ali Mahzarnia, Jacques A Stout, Robert J Anderson, Hae Sol Moon, Zay Yar Han, Kate Beck, Jeffrey N Browndyke, David B Dunson, Kim G Johnson, Richard J O’Brien, Alexandra Badea
Publikováno v:
Cerebral Cortex. 33:5307-5322
The selective vulnerability of brain networks in individuals at risk for Alzheimer’s disease (AD) may help differentiate pathological from normal aging at asymptomatic stages, allowing the implementation of more effective interventions. We used a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7463970c588bb9dbf96c83d114440959
https://doi.org/10.1093/cercor/bhac419
https://doi.org/10.1093/cercor/bhac419
Autor:
Lutz, Aida Kamalian, Sara G. Ho, Megha Patel, Alexandria Lewis, Arnold Bakker, Marilyn Albert, Richard J. O’Brien, Abhay Moghekar, Michael W.
Publikováno v:
Biomolecules; Volume 13; Issue 7; Pages: 1094
(1) Background: Despite the existence of well-established, CSF-based biomarkers such as amyloid-β and phosphorylated-tau, the pathways involved in the pathophysiology of Alzheimer’s disease (AD) remain an active area of research. (2) Methods: We m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::15e39174d0a92fdafeca52a87f2ca495
Autor:
Alexandra Badea, Kwan L Ng, Robert J Anderson, Jiangyang Zhang, Michael I Miller, Richard J O'Brien
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0216596 (2019)
We do not have a full understanding of the mechanisms underlying plasticity in the human brain. Mouse models have well controlled environments and genetics, and provide tools to help dissect the mechanisms underlying the observed responses to therapi
Externí odkaz:
https://doaj.org/article/980752181f064b5ead26b9876118ab26
Autor:
Ali Mahzarnia, Jacques A Stout, Robert J Anderson, Hae Sol Moon, Zay Yar Han, Kate Beck, Jeffrey N Browndyke, David B. Dunson, Kim G Johnson, Richard J O’Brien, Alexandra Badea
Brain connectomes provide untapped potential for identifying individuals at risk for Alzheimer’s disease (AD), and can help provide novel targets based on selective circuit vulnerability. Age, APOE4 genotype, and female sex are thought to contribut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56916a855ab94be52feb767ecface09c
https://doi.org/10.1101/2022.06.15.496331
https://doi.org/10.1101/2022.06.15.496331
Autor:
Yu Pang, Qiang Li, Xichao Ou, Hojoon Sohn, Zhiying Zhang, Junchen Li, Hui Xia, Kai Man Kam, Richard J O'Brien, Junying Chi, Shitong Huan, Daniel P Chin, Yan-lin Zhao
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e69267 (2013)
BACKGROUND: Genechip (CapitalBio, Beijing, China) is a system for diagnosing resistance to rifampin and isoniazid, which shows high efficiency in detecting drug-resistant tuberculosis. Here, we firstly evaluated the costs of Genechip for detecting th
Externí odkaz:
https://doaj.org/article/a7b380c368ab495aa2650f61748d7399
Autor:
Ann M. Loeffler, Joseph Keane, Ed Desmond, Philip A. LoBue, Charles L. Daley, Gerald H. Mazurek, Gail L. Woods, David M. Warshauer, Madhukar Pai, Michael K. Leonard, Thomas M. Shinnick, Richard J. O'Brien, Luca Richeldi, David M. Lewinsohn, David L. Cohn, Deborah A. Lewinsohn, Timothy R. Sterling, Max Salfinger
Publikováno v:
Clinical Infectious Diseases. 64:e1-e33
Background. Individuals infected with Mycobacterium tuberculosis (Mtb) may develop symptoms and signs of disease (tuberculosis disease) or may have no clinical evidence of disease (latent tuberculosis infection [LTBI]). Tuberculosis disease is a lead
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ad5c248729136b206db2beaee64db34
https://doi.org/10.1093/cid/ciw694
https://doi.org/10.1093/cid/ciw694
Autor:
Kari‐Elise T. Codispoti, Lori L. Beason‐Held, Michael A. Kraut, Richard J. O’Brien, Gay Rudow, Olga Pletnikova, Barbara Crain, Juan C. Troncoso, Susan M. Resnick
Publikováno v:
Brain and Behavior
Asymptomatic Alzheimer disease (ASYMAD) is characterized by normal cognition despite substantial AD pathology. To identify factors contributing to cognitive resilience, we compared early changes in regional cerebral blood flow (rCBF) in individuals s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::860d352a4b1b6e87ee497bbd15310e27
https://doi.org/10.1002/brb3.47
https://doi.org/10.1002/brb3.47
Autor:
Mel Spigelman, Richard J. O'Brien
Publikováno v:
Clinics in Chest Medicine. 26:327-340
This article reviews two classes of compounds that have advanced into phase II and III clinical trials, long-acting rifamycins and fluoroquinolones, and a number of other drugs that have entered or may enter clinical development in the near future.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::358b5048d86dc91879363f74a6e010bd
https://doi.org/10.1016/j.ccm.2005.02.013
https://doi.org/10.1016/j.ccm.2005.02.013